Access to Medicine
Every two years, the Access to Medicine Foundation, an independent non-profit organization founded in 2005, benchmarks 20 of the world’s largest pharmaceutical companies based on their efforts to advance global access to medicines.
Our company is committed to driving health equity by improving sustainable access to high-quality solutions for all communities and patients in need.
Our Strong Performance
We rank 7th in the ATM Index 2024, performing above industry standards and confirming our progress in expanding access to health to serve populations in need in low- and middle-income countries (LMICs).
We rank 6th in Research & Development with our structured access planning framework, our full package of access plans for our assets to reach low- and middle-income countries and excellence in capacity-building initiatives.
We strongly perform through our comprehensive access to medicine strategy, our pricing strategies in upper-middle, lower-middle and low-income countries, our mechanism to ensure continuous supply, our high-quality capacity building initiatives for health system strengthening, manufacturing and supply chain, and our long-standing commitment and leadership in the fight against the neglected tropical disease, schistosomiasis.
In line with our Company’s Sustainability Strategy, we advance in our goal to reach over 170 million people/patients in LMICs per year with our healthcare and global health portfolio of products by 2030.
Facts & Figures
-
113
the low- and middle-income countries in the scope of the ATM Index 2024
-
81
the diseases in the scope of the ATM Index 2024
Access to Medicine Index 2024
The Access to Medicine Foundation benchmarks 20 of the world’s largest pharmaceutical companies across a range of indicators grouped into three areas: Governance of Access, R&D and Product Delivery.